Skip to main content
2025 PharmSci 360 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Listen Now

Bioanalytics
Partner Presentation

Bioanalytical Strategies for Therapeutic Drugs and Their Conjugates (ADCs, Oligos, siRNA, ASOs and AOCs/ARCs) by QqQ/HRMS. Strategies and Case Studies

Tuesday, November 11, 2025
3:30 PM - 4:30 PM CT
Location:360 Stage #2, Exhibit Hall

Sponsored By 
Bioanalytics Partner Presentation-Bioanalytics

Description: Bioanalysis of next-generation Antibody Drug Conjugates (ADCs), Antibody-RNA Conjugates (ARCs), and oligonucleotide therapeutics increasingly relies on hybrid LC-MS/MS for both quantitative and structural characterization. Hybrid LC-MS/MS efficiently monitors total antibodies, conjugates like siRNA or ASO, and toxic payloads. This presentation will focus on bioanalytical strategies and challenges in analyzing conjugated therapeutics, using case studies to demonstrate how robust LC-MS/MS workflows support comprehensive characterization and drug development across oncology, genetic, and rare disease indications.

Learning Objectives:

  • Understand the Role of Hybrid LC-MS/MS in Conjugated Therapeutics Learn how hybrid LC-MS/MS is applied for both quantitative and structural analysis of next-generation therapeutics such as ADCs, ARCs, and oligonucleotides.
  • Identify Key Bioanalytical Challenges and Strategies Explore the specific analytical hurdles in monitoring complex conjugates (e.g., siRNA, ASO, toxic payloads) and how tailored LC-MS/MS workflows address these challenges.
  • Review Case Studies Across Therapeutic Areas Analyze real-world examples demonstrating how LC-MS/MS supports drug development in oncology, genetic disorders, and rare diseases through comprehensive characterization.